ASTRAZENECA, the pha­r­maceutical giant which virtually became a household name during the Covid-19 pandemic, has admitted that its Covishield vaccine could cause rare side effects, including blood clots and low platelet count.

The pharma giant is being sued in a class action over claims that its vaccine, developed with the University of Oxford, caused death and serious injury in dozens of cases.

“It is admitted that the AZ vaccine can, in very rare cases, cause TTS (Thrombosis with Thrombocytopenia Syndrome). The causal mechanism is not known,” the company said in court documents, The Telegraph reported.

Covishield was developed by the British-Swedish company in collaboration with Oxford University, and produced by the Serum Institute of India. It was widely administered in over 150 countries.

Some studies conducted during the pandemic found the vaccine was 60 to 80 per cent effective in protecting against the novel coronavirus, according to The Independent.

But one of the complainants alleged that the vaccine caused him a permanent brain injury after he developed a blood clot, preventing him from working.

While the company has contested these claims, the court submission marks the first time it has admitted that the vaccine can cause side-effects that are characterised by blood clots and a low blood platelet count in humans.

“Further, TTS can also occur in the absence of the AZ vaccine (or any vaccine). Causation in any individual case will be a matter for expert evidence,” it added.

The admission by AstraZeneca runs counter to the company’s insistence in 2023 that it would “not accept that TTS is caused by the vaccine at a generic level”, according to The Independent.

Scientists first identified a link between the vaccine and a new illness called vaccine-induced immune thrombocytopenia and thrombosis (VITT) in March 2021.

The UK government has indemnified Astra­Zeneca against any legal action but has so far refused to intervene, according to The Telegraph.

According to the Council for International Organisat­ions of Medical Sciences, “very rare” side effects are those reported in less than 1 in 10,000 cases.

Published in Dawn, May 1st, 2024

Opinion

Editorial

Furtive measures
Updated 07 Sep, 2024

Furtive measures

The entire electoral exercise has become riddled with controversy, yet ECP seems unwilling to address the lingering questions about the polls.
PCB hot seat
Updated 07 Sep, 2024

PCB hot seat

MOHSIN Naqvi is facing criticism from all quarters. Pakistan’s cricket board chief, who is also the country’s...
Rapes most foul
07 Sep, 2024

Rapes most foul

UNTIL the full force of the law is applied on perpetrators, insecurity will stalk Pakistan’s girl children and...
Positive overtures
Updated 06 Sep, 2024

Positive overtures

It is hoped politicians refusing to frame Balochistan’s problems in black and white is taken as a positive overture by the province's people.
Capital poll delay
06 Sep, 2024

Capital poll delay

THE ECP has cancelled the local government elections in Islamabad for the third time subsequent to a recent ...
Perks galore
06 Sep, 2024

Perks galore

A parasitic bureaucracy still upholds colonial customs whereby a struggling citizenry and flood victims are subservient to status.